

TRENDS EN VOORKOMEN VAN  
ANTIBIOTICUM RESISTENTIE IN  
*SALMONELLA*, *CAMPYLOBACTER* EN  
*E. COLI* GEÏSOLEERD UIT VOEDING

# HOE ANTIBIOTICUM RESISTENTIE ZICH VERSPREIDT - DE OH BENADERING



# ECDC & EFSA – BUNDELING VAN DE KRACHTEN

## COMMISSION IMPLEMENTING DECISION 2013/652/EU (12 NOVEMBER 2013)

<p><b>Animal / Food</b></p> <ul style="list-style-type: none"> <li>• Poultry             <ul style="list-style-type: none"> <li>▪ Laying hens</li> <li>▪ Broilers</li> <li>▪ Turkeys*</li> </ul> </li> <li>• Pigs</li> <li>• Calves* &lt; 1 year of age</li> </ul> <p><b>Food</b></p> <ul style="list-style-type: none"> <li>• Meat             <ul style="list-style-type: none"> <li>▪ Beef</li> <li>▪ Pork</li> <li>▪ Broiler meat</li> </ul> </li> </ul>	<p><b>Zoonotic bacteria</b></p> <ul style="list-style-type: none"> <li>• <i>Salmonella</i> spp.</li> <li>• <i>C. jejuni</i> / <i>C. coli</i></li> <li>• ESBL-/AmpC-/Carbapenemase-producing <i>Salmonella</i></li> </ul> <p><b>Indicator bacteria</b></p> <ul style="list-style-type: none"> <li>• <i>E. coli</i></li> <li>• <i>E. faecalis</i> / <i>E. faecium</i></li> <li>• ESBL-/AmpC-/Carbapenemase-producing <i>E. coli</i></li> </ul>
--	--

\* + 10,000 t/year



### SCIENTIFIC REPORT

APPROVED: 31 January 2020

doi: 10.2903/j.efsa.2020.6007

### The European Union Summary Report on Antimicrobial Resistance in zoonotic and indicator bacteria from humans, animals and food in 2017/2018


European Food Safety Authority and  
European Centre for Disease Prevention and Control

**TECHNICAL DOCUMENT**

**EU protocol for harmonised monitoring of antimicrobial resistance in human *Salmonella* and *Campylobacter* isolates**

June 2016

<https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/antimicrobial-resistance-Salmonella-Campylobacter-harmonised-monitoring.pdf>



# SURVEILLANCE ANTIBIOTICUM PANELS

## WHO Critically Important Antimicrobials for Human Medicine 6<sup>th</sup> revision Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) November 2018

Summary of categorization and prioritization of antimicrobials categorized as Critically Important, Highly Important and Important

Antimicrobial class	Criterion / Prioritization factor (Yes = ●)					
	C1	C2	P1	P2	P3	
<b>CRITICALLY IMPORTANT ANTIMICROBIALS</b>						
<i>HIGHEST PRIORITY</i>						
<b>Highest Priority</b>	Cephalosporins (3 <sup>rd</sup> , 4 <sup>th</sup> and 5 <sup>th</sup> generation)	●	●	●	●	●
	Glycopeptides	●	●	●	●	●
	Macrolides and ketolides	●	●	●	●	●
	Polymyxins	●	●	●	●	●
	Quinolones	●	●	●	●	●
<i>HIGH PRIORITY</i>						
<b>Critically Important</b>	Aminoglycosides	●	●		●	●
	Ansamycins	●	●	●	●	
	Carbapenems and other penems	●	●	●	●	
	Glycylcyclines	●	●	●		
	Lipopeptides	●	●	●		
	Monobactams	●	●	●		
	Oxazolidinones	●	●	●		
	Penicillins (antipseudomonal)	●	●		●	
	Penicillins (aminopenicillins)	●	●		●	●
	Penicillins (aminopenicillins with β-lactamase inhibitors)	●	●		●	●
	Phosphonic acid derivatives	●	●	●	●	
	Drugs used solely to treat tuberculosis / mycobacterial diseases	●	●	●	●	
	<b>HIGHLY IMPORTANT ANTIMICROBIALS</b>					
	C1	C2	P1	P2	P3	

**C1 | Criterion 1**

The antimicrobial class is the sole, or one of limited available therapies, to treat serious bacterial infections in people.

**C2 | Criterion 2**

The antimicrobial class is used to treat infections in people caused by either: (1) bacteria that may be transmitted to humans from nonhuman sources, or (2) bacteria that may acquire resistance genes from nonhuman sources.

**P1 | Prioritization factor 1**

Large number of people in the community or in certain high-risk populations (e.g. patients with serious infections in health care settings), who are affected by diseases for




Antibioticum
Tetracycline
Nalidixic acid
Ciprofloxacin
Erythromycin
Gentamicin
Streptomycin



Antibioticum
Ampicillin
Cefotaxime
Ceftazidime
Meropenem
Nalidixic acid
Ciprofloxacin
Tetracycline
Colistin
Gentamicin
Trimethoprim
Sulfamethoxazole
Chloramphenicol
Azithromycin
Tigecycline



# AMR IN VOEDING : SURVEILLANCE PROGRAMMA'S



*Campylobacter* spp.

- *C. coli* in pork (end in 2015)
- *C. jejuni* in poultry meat

• **AMR Priority :**

- Profile of resistance and emerging resistance to macrolides



*Salmonella* spp.

- *Salmonella* on broilers and laying hens National Control Plan (yearly).
- *Salmonella* from poultry neck skin (odd years)
- *Salmonella* in pork and bovine carcasses (even years)
- *Salmonella* in food and feed

• **AMR Priority :**

- $\beta$ -lactams and carbapenems R
- Colistin R
- Tigecycline R
- Co-resistance to CIA
- MDR



*E. coli* ( $\beta$ -lactamase/Carbapenemase producing)

- Detection of ESBL:
  - ESBL in poultry meat (since 2011)
  - ESBL in pork meat (since 2013)
  - ESBL in beef meat (since 2013)
  - ESBL in fish (since 2015)
  - ESBL in milk (since 2017)
  - ESBL in fruits and vegetables (since 2019)

• **AMR Priority :**

- Carbapenems R
- Colistin R
- Tigecycline R
- Co-resistance to CIA
- MDR




Directorate-General for Health and Food Safety (DG SANTE)




# AMR IN *SALMONELLA* SPP. GEÏSOLEERD VAN KARKASSEN VAN VLEESKIPPEN (SLACHTHUIS)


**S. Enteritidis**



**S. Infantis**



**S. Paratyphi B**



■ Amp ■ Smx ■ Tet ■ Tmp ■ Chl ■ Cip ■ Nal ■ Fot ■ Col



■ Amp ■ Smx ■ Tet ■ Tmp ■ Chl ■ Cip ■ Nal ■ Fot ■ Col

■ Amp ■ Smx ■ Tet ■ Tmp ■ Chl ■ Cip ■ Nal ■ Fot ■ Col

## Trends 2014-2018


↑ Col	↑ Amp, Tmp	↑ Smx, Col
↓ Cip	↓ Tet	↓ Cip Nal Fot
	= Cip, Nal, Smx	

# GEVOELIGHEID EN MULTIPELE RESISTENTIE




# AMR IN *SALMONELLA* SPP. GEÏSOLEERD VAN KARKASSEN VAN VARKENS (SLACHTHUIS)

## S. Derby




■ Amp ■ Smx ■ Tet ■ Tmp ■ Chl ■ Cip ■ Nal ■ Fot ■ Col

## S. Typhimurium




■ Amp ■ Smx ■ Tet ■ Tmp ■ Chl ■ Cip ■ Nal ■ Fot ■ Col

## Monophasic S. Typhimurium



■ Amp ■ Smx ■ Tet ■ Tmp ■ Chl ■ Cip ■ Nal ■ Fot ■ Col



## S. Typhimurium var O-




■ Amp ■ Smx ■ Tet ■ Tmp ■ Chl ■ Cip ■ Nal ■ Fot ■ Col



# GEVOELIGHEID EN MULTIPELE RESISTENTIE




# CAMPYLOBACTER JEJUNI GEVOGELTE (VLEES)




Resistentie profiel	n	%
Gevoelig	49	30,25
Cip	6	3,70
CipNal	24	14,81
CipNalStrTet	17	10,49
<b>CipNalTet</b>	<b>61</b>	<b>37,65</b>
CipTet	1	0,62
Ery	1	0,62
Tet	3	1,85
<b>Totaal</b>	<b>162</b>	

## Campylobacter jejuni



# PREVALENTIE VAN *E. COLI* ESBL IN VERS VLEES

## Belgium situation, 2017-2019




EFSA Journal 2020;18(3):6007

## European situation, 2017-2018


# SURVEILLANCE B-LACTAMASE OF CARBAPENEMASE PRODUCERENDE *E. COLI* UIT GEVOGELTE



Broiler Fresh meat




Broiler Fresh Meat




- Daling fluoroquinolonen
- Graad multipele resistentie stabiel

Trends in MDR



# SURVEILLANCE B-LACTAMASE OF CARBAPENEMASE PRODUCERENDE *E. COLI* UIT VARKENSVLEES


Fresh pork meat at retail



- Voor talrijke antibiotica een dalende trend (ook voor de CIA en fluoroquinolonen)
- 1 isolaat had een MDR profiel dat ESBL + FQ + COL combineert


Daling van multiplere resistentie van 100% (2017, 2018) naar 85,72% (2019)

Fresh pork meat



# SURVEILLANCE B-LACTAMASE OF CARBAPENEMASE PRODUCERENDE *E. COLI* UIT RUNDVLEES


Beef fresh meat at retail



- Positieve trends
- Daling voor tal van antibiotica waaronder de CIA en fluoroquinolonen

Daling van multiplere resistentie van 100% (2017, 2018) naar 60% (2019)

Fresh Beef Meat



BEDANKT

## Contact

Sciensano  
Dienst Voedselpathogenen  
NRL AMR

Dorine Ghenne • [dorine.ghenne@sciensano.be](mailto:dorine.ghenne@sciensano.be) • +32 2 642 51 04

Maria Cristina Garcia Graells • [mariacristina.garciagrealles@sciensano.be](mailto:mariacristina.garciagrealles@sciensano.be) • +32 2 642 53 73

Koenraad Van Hoorde • [koenraad.vanhoorde@sciensano.be](mailto:koenraad.vanhoorde@sciensano.be) • +32 2 642 52 16